Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs